DDrare: Database of Drug Development for Rare Diseases

168. エーラス・ダンロス症候群　［臨床試験数：7，薬物数：14（DrugBank：10），標的遺伝子数：17，標的パスウェイ数：53］

Searched query = "Ehlers Danlos syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Drug = 0.9% sodium chloride injection; Bupivacaine; Bupivacaine injection 0.5%; Celiprolol; Chloride; Control; Irbesartan; Lidocaine; Lidocaine injection 2%; Mecasermin; Mind-body therapy; Riboflavin; Saline; Sodium chloride

No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04036305	July 26, 2019	2 September 2019	Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers	Local Anesthetic Response in Ehlers-Danlos Syndrome (EDS) and Healthy Volunteers	Ehlers-Danlos Syndrome;Anesthesia, Local	Drug: 0.9% Sodium Chloride Injection;Drug: Lidocaine Injection 2%;Drug: Bupivacaine Injection 0.5%	Vanderbilt University Medical Center	University of Calgary	Recruiting	18 Years	N/A	All	230	Phase 3	United States
2	NCT02597361	January 2016	23 July 2018	Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)	Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome: a Double Blind, Randomized, Placebo Controlled, Multicenter Trial.	Ehlers-Danlos Syndrome, Vascular Type	Drug: Irbesartan;Drug: Placebo	Assistance Publique - Hôpitaux de Paris	Ministry of Health, France	Recruiting	18 Years	70 Years	All	108	Phase 3	France
3	EUCTR2015-001065-76-FR	28/09/2015	18 January 2016	N/A	N/A - ARCADE	MedDRA version: 18.0 Level: PT Classification code 10014316 Term: Ehlers-Danlos syndrome System Organ Class: 10010331 - Congenital, familial and genetic disorders	Trade Name: IRBESARTAN Product Name: IRBESARTAN Pharmaceutical Form: Coated tablet INN or Proposed INN: irbesartan Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Coated tablet Route of administration of the placebo: Oral use	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)		Authorised			Female: yes Male: yes			France
4	NCT01446783	September 2011	19 February 2015	IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients	IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients	Ehlers-Danlos Syndrome, Classic	Drug: mecasermin;Drug: Saline	Bispebjerg Hospital		Not recruiting	18 Years	N/A	Both	15	N/A	Denmark
5	NCT01307527	November 2008	19 February 2015	Riboflavin Corneal Crosslinking for Brittle Cornea Syndrome and Ehlers-Danlos Syndrome Type VI		Brittle Cornea Syndrome;Ehlers-Danlos Syndrome Type 6	Drug: Riboflavin;Device: Kera-X	Hadassah Medical Organization		Recruiting	18 Years	N/A	Both	1	N/A	Israel
No.	TrialID	Date_ enrollement	Last_Refreshed_ on	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	NCT00190411	October 2003	19 February 2015	Celiprolol in Patients With Ehlers-Danlos Syndrome, Vascular Type	Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome	EHLERS-DANLOS SYNDROME, TYPE IV, AUTOSOMAL DOMINANT;CHROMOSOME 2q31.2 DELETION SYNDROME	Drug: celiprolol;Drug: Control	Assistance Publique - Hôpitaux de Paris	Aventis Pharmaceuticals	Not recruiting	15 Years	65 Years	Both	54	Phase 4	France
7	NCT00001966	January 2000	19 February 2015	Mind-Body Therapy for Pain in Ehlers-Danlos Syndrome	A Pilot Study of Mind-Body Therapy for Chronic Pain in Ehlers-Danlos Syndrome	Ehlers-Danlos Syndrome;Pain	Drug: Mind-body therapy	National Human Genome Research Institute (NHGRI)		Not recruiting	N/A	N/A	Both	40	Phase 2	United States

先頭へ